6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: A Children's Oncology Group study

Blood

Volumn 124, Issue 15, 2014, Pages 2345-2353

  Bhatia, Smita ^a   Landier, Wendy ^a   Hageman, Lindsey ^a   Kim, Heeyoung ^a   Chen, Yanjun ^a   Crews, Kristine R ^b   Evans, William E ^b   Bostrom, Bruce ^c   Casillas, Jacqueline ^d   Dickens, David S ^e   Maloney, Kelly W ^f   Neglia, Joseph P ^g   Ravindranath, Yaddanapudi ^h   Ritchey, A Kim ⁱ   Wong, F Lennie ^a   Relling, Mary V ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^f Children's Hospital Colorado   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

ⁱ CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN AMERICAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CAREGIVER; CAUCASIAN; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; COLLEGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; HOSPITALIZED CHILD; HOUSEHOLD; HUMAN; LOWEST INCOME GROUP; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOTHER; PATIENT COMPLIANCE; PRESCHOOL CHILD; RACE DIFFERENCE; RECURRENCE RISK; SCHOOL CHILD; YOUNG ADULT; ANCESTRY GROUP; CLINICAL TRIAL; DEMOGRAPHY; ETHNOLOGY; INFANT; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REGRESSION ANALYSIS;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DEMOGRAPHY; FEMALE; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84907612579     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-552166     Document Type: Article

References (41)

1. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008;112(2):416-432.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
3. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24.
4. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-136.
5. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012;119(15):3512-3522.
6. Koren G, Ferrazini G, Sulh H, et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med. 1990;323(1):17-21.
7. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9):2817-2823.
8. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7(12):1816-1823.
9. Schmiegelow K, Schrøder H, Gustafsson G, et al; Nordic Society for Pediatric Hematology and Oncology. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol. 1995;13(2):345-351.
10. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336(8709):225-229.
11. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer. 1995;72(4):1004-1006.
12. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ. 1993;306(6887):1239-1240.
13. Lau RC, Matsui D, Greenberg M, Koren G. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;30(2):85-90.
14. Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer. 1986;58(5):1179-1184.
15. MacDougall LG, Wilson TD, Cohn R, Shuenyane EN, McElligott SE. Compliance with chemotherapy in childhood leukaemia in Africa. S Afr Med J. 1989;75(10):481-484.
16. Smith SD, Rosen D, Trueworthy RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979;43(1):169-173.
17. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012;30(17):2094-2101.
18. Humes KR, Jones NA, Ramirez RR. Overview of Race and Hispanic Origin: 2010. Washington, DC: US Department of Commerce; 2011.
19. Su Y, Hon YY, Chu Y, Van de Poll ME, Relling MV. Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. J Chromatogr B Biomed Sci Appl. 1999;732(2):459-468.
20. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126(8):608-614.
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
23. Kohl M, Heinze G. PSHREG: A SAS® Macro for Proportional and Nonproportional Substribution Hazards Regression With Competing Risk Data. Technical Report 08/2012. Vienna, Austria: Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems; 2012.
24. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987.
25. Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10(3):195-216.
26. Yang Y, Thumula V, Pace PF, Banahan BF III, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178-2188, discussion 2150-2151.
27. Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24.
28. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249-255.
29. McQuaid EL, Everhart RS, Seifer R, et al. Medication adherence among Latino and non-Latino white children with asthma. Pediatrics. 2012;129(6):e1404-e1410.
30. Osborn CY, Cavanaugh K, Wallston KA, et al. Health literacy explains racial disparities in diabetes medication adherence. J Health Commun. 2011;16(suppl 3):268-278.
31. Egede LE, Lynch CP, Gebregziabher M, et al. Differential impact of longitudinal medication non-adherence on mortality by race/ethnicity among veterans with diabetes. J Gen Intern Med. 2013;28(2):208-215.
32. Adams AS, Uratsu C, Dyer W, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173(1):54-61.
33. Fredriksen-Goldsen KI, Shiu CS, Starks H, et al. "You must take the medications for you and for me": family caregivers promoting HIV medication adherence in China. AIDS Patient Care STDS. 2011;25(12):735-741.
34. Aggarwal B, Liao M, Mosca L. Medication adherence is associated with having a caregiver among cardiac patients. Ann Behav Med. 2013;46(2):237-242.
35. Knowlton AR, Yang C, Bohnert A, Wissow L, Chander G, Arnsten JA. Informal care and reciprocity of support are associated with HAART adherence among men in Baltimore, MD, USA. AIDS Behav. 2011;15(7):1429-1436.
36. Beals KP, Wight RG, Aneshensel CS, Murphy DA, Miller-Martinez D. The role of family caregivers in HIV medication adherence. AIDS Care. 2006;18(6):589-596.
37. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002;100(6):1957-1964.
38. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290(15):2008-2014.
39. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 2000;18(4):813-823.
40. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32(5):345-356.
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.